NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Recruiting
Observational Study
Cutaneous Melanoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 250 (estimated)
- Sponsor
- AC Camargo Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.
Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.
The study compares outc…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.
Exclusion Criteria:
* Patients without sufficient clinical or follow-up data.
* Patients who do not provide informed consent (for p…
Contacts
No contact information available.